Literature DB >> 53262

Recognitive specificity of human cytotoxic T lymphocytes. I. Antigen-specific inhibition of human cell-mediated lympholysis.

P M Sondel, F H Bach.   

Abstract

The specificity of antigen recognition by in vitro sensitized human cytotoxic T lymphocytes (CTLs) has been studied using a sensitive cell-mediated lympholysis (CML) assay. Frequently, high levels of cytotoxicity are observed on third-party targets unrelated to sensitizing or responding cells; however, no cytotoxicity differing significantly from zero has been observed on targets autologous to the responding CTLs. This "cross-killing" of third-party target cells has been observed when stimulating and third-party cells bear no cross-reacting serologically defined (SD) antigens, thought to be the target antigens recognized by CTLs. CML-blocking studies, using unlabeled normal human lymphocytes to inhibit 51Cr release from radiolabeled target cells, have shown that cross-killing, even in the absence of shared SD determinants, results from CTLs recognizing antigens shared by the third-party targets and the initial stimulating population. Furthermore, these antigens have been mapped to the major histocompatibility complex (MHC). The ability of human CTLs to specifically recognize MHC-controlled antigens not detected serologically suggests that SD antigens may be recognized differently by alloantisera and CTLs, or that MHC antigens other than SD may be the targets of CTLs in CML.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 53262      PMCID: PMC2190082          DOI: 10.1084/jem.142.6.1339

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  Alloimmune cytotoxic T cells: Evidence that they recognize serologically defined antigens and bear clonally restricted receptors.

Authors:  M J Bevan
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

2.  MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS.

Authors:  P I TERASAKI; J D MCCLELLAND
Journal:  Nature       Date:  1964-12-05       Impact factor: 49.962

3.  Serological cross-reactivity in the HL-A system.

Authors:  K K Mittal; P I Terasaki
Journal:  Tissue Antigens       Date:  1974

4.  Qualitative and quantitative studies of cytotoxic immune cells.

Authors:  T G Canty; J R Wunderlich; F Fletcher
Journal:  J Immunol       Date:  1971-01       Impact factor: 5.422

5.  Cell mediated lympholysis in man after sensitization of effector lymphocytes through mixed leukocyte cultures.

Authors:  J Lightbody; D Bernoco; V C Miggiano; R Ceppellini
Journal:  G Batteriol Virol Immunol       Date:  1971 Sep-Dec

6.  Mixed lymphocyte cultures produce effector cells: model in vitro for allograft rejection.

Authors:  P Häyry; V Defendi
Journal:  Science       Date:  1970-04-03       Impact factor: 47.728

7.  Cytotoxicity: specificity after in vitro sensitization.

Authors:  S Solliday; F H Bach
Journal:  Science       Date:  1970-12-25       Impact factor: 47.728

8.  On the specificity of cell-mediated cytotoxicity in vitro.

Authors:  E A Svedmyr; R J Hodes
Journal:  Cell Immunol       Date:  1970-12       Impact factor: 4.868

9.  Histocompatibility matching. VI. Miniaturization of the mixed leukocyte culture test: a preliminary report.

Authors:  R J Hartzman; M Segall; M L Bach; F H Bach
Journal:  Transplantation       Date:  1971-03       Impact factor: 4.939

10.  Immunologic functions of isolated human lymphocyte subpopulations. III. Specific allogeneic lympholysis mediated by human T cells alone.

Authors:  P M Sondel; L Chess; R P MacDermott; S F Schlossman
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

View more
  11 in total

1.  Differential recognition of the serologically defined HLA-A2 antigen by allogeneic cytotoxic T cells. I. Population studies.

Authors:  S Horai; J J van der Poel; E Goulmy
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

2.  Sensitization of lymphocytes against pooled allogeneic cells. I. Generation of cytotoxicity against autologous human lymphoblastoid cell lines.

Authors:  J M Zarling; F H Bach
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

3.  Deficient expression of class-I HLA in some cases of acute leukemia.

Authors:  W L Elkins; A Pickard; G R Pierson
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

4.  Bovine T lymphocytes. I. Generation and maintenance of an interleukin-2-dependent, cytotoxic T-lymphocyte cell line.

Authors:  K S Picha; P E Baker
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

5.  HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.

Authors:  P M Sondel; J A Hank; T Wendel; B Flynn; M J Bozdech
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

6.  Recognition of human minor alloantigen(s) by cytotoxic lymphocytes in vitro.

Authors:  W L Elkins; G Pierson; W Negendank; K S Zier
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

Review 7.  The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.

Authors:  Ryan J Sullivan; Patricia M Lorusso; Keith T Flaherty
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

8.  Direct cytotoxicity against chicken erythrocytes in mice. III. Degrees of radiosensitivity and cross-reactivity of cytotoxicity, delayed hypersensitivity and antibody production.

Authors:  C Kubo; K Nomoto; K Taniguchi; F Nanishi; Y Shimamoto; K Takeya
Journal:  Immunology       Date:  1979-08       Impact factor: 7.397

9.  HLA-D region-associated determinants serve as targets for human cell-mediated lysis.

Authors:  C Feighery; P Stastny
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

10.  Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors.

Authors:  K F Lindahl; D B Wilson
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.